Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Marissa, Balak"'
Publikováno v:
PLoS ONE, Vol 4, Iss 8, p e6862 (2009)
Weight-bearing stepping, without supraspinal re-connectivity, can be attained by treadmill training in an animal whose spinal cord has been completely transected at the lower thoracic level. Repair of damaged tissue and of supraspinal connectivity/ci
Externí odkaz:
https://doaj.org/article/8af5ae39189a4816818bf18d8a4125e4
Autor:
Yixuan Gong, Romel Somwar, Katerina Politi, Marissa Balak, Juliann Chmielecki, Xuejun Jiang, William Pao
Publikováno v:
PLoS Medicine, Vol 4, Iss 10, p e294 (2007)
Mutations in the epidermal growth factor receptor (EGFR) gene are associated with increased sensitivity of lung cancers to kinase inhibitors like erlotinib. Mechanisms of cell death that occur after kinase inhibition in these oncogene-dependent tumor
Externí odkaz:
https://doaj.org/article/e1d737c242f048f6b1a3dab9c2f98547
Autor:
Jacob R. Haling, David A. Ruddy, Giordano Caponigro, Jodi Meltzer, Scott Delach, Daniel P. Rakiec, Marissa Balak, Michael G. Acker, Joshua M. Korn, Ping Wang, Kelli-Ann Monaco, Caroline Emery, Alyson K. Freeman
Publikováno v:
Molecular Cancer Research. 15:1431-1444
Alterations in MEK1/2 occur in cancers, both in the treatment-naïve state and following targeted therapies, most notably BRAF and MEK inhibitors in BRAF-V600E–mutant melanoma and colorectal cancer. Efforts were undertaken to understand the effects
Autor:
Rui Zhao, David A. Ruddy, Frank Stegmeier, Justina X. Caushi, Alina Raza, Joshua M. Korn, Daniel P. Rakiec, Marissa Balak, Franziska Michor, Derek Y. Chiang, Viveksagar Krishnamurthy Radhakrishna, Iris Kao, Michael R. Schlabach, Vesselina G. Cooke, Pamela Shaw, Michael Palmer, Angad P Singh, Rebecca Leary, William R. Sellers, Nicholas Keen, Matthew M Hims, Elizabeth Ackley, Hyo-eun C. Bhang
Publikováno v:
Nature Medicine. 21:440-448
Resistance to cancer therapies presents a significant clinical challenge. Recent studies have revealed intratumoral heterogeneity as a source of therapeutic resistance. However, it is unclear whether resistance is driven predominantly by pre-existing
Autor:
Benjamin H Lee, Hung Huynh, Robert Schlegel, David A. Ruddy, Dalila Sellami, Marissa Balak, Adnan Derti, David Chen, Yan Wang, Michael Palmer, Khee Chee Soo, Huaixiang Hao, Stephen L. Chan, Alan Huang, Panisa Pochanard, Richard Ong, David Yang, Andrew X. Zhu, Manway Liu
Publikováno v:
Molecular cancer therapeutics. 14(5)
Hepatocellular carcinoma (HCC) is the third leading cause of cancer deaths worldwide and hyperactivation of mTOR signaling plays a pivotal role in HCC tumorigenesis. Tuberous sclerosis complex (TSC), a heterodimer of TSC1 and TSC2, functions as a neg
Autor:
William Pao, Marissa Balak, Vincent A. Miller, Jenifer L. Marks, Gregory J. Riely, Jonathan F. Bean, Marc Ladanyi
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 14(22)
Purpose: Somatic mutations in the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) gene are associated with sensitivity of lung adenocarcinomas to the EGFR tyrosine kinase inhibitors, gefitinib and erlotinib. Acquired drug resist
Autor:
Juliann Chmielecki, Romel Somwar, Yixuan Gong, Xuejun Jiang, William Pao, Katerina Politi, Marissa Balak
Publikováno v:
PLoS Medicine, Vol 4, Iss 10, p e294 (2007)
Mutations in the epidermal growth factor receptor (EGFR) gene are associated with increased sensitivity of lung cancers to kinase inhibitors like erlotinib. Mechanisms of cell death that occur after kinase inhibition in these oncogene-dependent tumor
Autor:
Yixuan, Gong, Romel, Somwar, Katerina, Politi, Marissa, Balak, Juliann, Chmielecki, Xuejun, Jiang, William, Pao
Publikováno v:
PLoS Medicine
Background Mutations in the epidermal growth factor receptor (EGFR) gene are associated with increased sensitivity of lung cancers to kinase inhibitors like erlotinib. Mechanisms of cell death that occur after kinase inhibition in these oncogene-depe
Autor:
Viveksagar Krishnamurthy Radhakrishna, David A. Ruddy, Pamela Shaw, Justina X. Caushi, Marissa Balak, Nicholas Keen, Elizabeth Ackley, Daniel P. Rakiec, Iris Kao, Frank Stegmeier, William R. Sellers, Rui Zhao, Hyo-eun C. Bhang, Vesselina G. Cooke, Michael Palmer, Michael R. Schlabach, Franziska Michor, Joshua M. Korn
Publikováno v:
Cancer Research. 75:2847-2847
Targeted therapies, such as erlotinib and imatinib, lead to dramatic clinical responses, but the emergence of resistance presents a significant challenge. Recent studies have revealed intratumoral heterogeneity as a potential source for the emergence
Autor:
Maureen F. Zakowski, Gregory J. Riely, Romel Somwar, William Pao, Marissa Balak, Vincent A. Miller, Marc Ladanyi, Ouathek Ouerfelli, Anne C. Chiang, Guangli Yang, Mark G. Kris, Allan R. Li, Yixuan Gong
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 12(21)
Purpose: In patients whose lung adenocarcinomas harbor epidermal growth factor receptor (EGFR) tyrosine kinase domain mutations, acquired resistance to the tyrosine kinase inhibitors (TKI) gefitinib (Iressa) and erlotinib (Tarceva) has been associate